CatalystFDA/Bio

Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy

Barclays downgrade despite FDA approval signals mixed analyst sentiment on SMA therapy.

What changed

Barclays downgrade despite FDA approval signals mixed analyst sentiment on SMA therapy.

Why it matters

Barclays downgrade despite FDA approval signals mixed analyst sentiment on SMA therapy. — impact context not separately stored; see What changed.

Sources